PTIX - Protagenic Therapeutics, Inc.\new

0.74
-0.560   -75.676%

Share volume: 1,922,073
Last Updated: 01-02-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.30
-0.56
-0.43%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
52%
Profitability 35%
Dept financing 46%
Liquidity 38%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
-54.32%
6 Months
-74.13%
1 Year
166.09%
2 Year
-34.51%
Key data
Stock price
$0.74
P/E Ratio 
0.00
DAY RANGE
$0.70 - $1.27
EPS 
-$3.97
52 WEEK RANGE
$0.18 - $14.28
52 WEEK CHANGE
$166.09
MARKET CAP 
2.020 M
YIELD 
N/A
SHARES OUTSTANDING 
1.935 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
-0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Garo H. Armen
Region: US
Website: protagenic.com
Employees: 2
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide.

Recent news